Beta-adrenoceptor blockers;Hemmstoffe von beta-adrenozeptoren

Pharmazie in Unserer Zeit

Volumn 33, Issue 6, 2004, Pages 442-449

  Griffin, Perry P ^a   Schubert Zsilavecz, Manfred ^a   Stark, Holger ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ACEBUTOLOL; ALPRENOLOL; ATENOLOL; BEFUNOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; BUPRANOLOL; CALCIUM ANTAGONIST; CARTEOLOL; DICHLORISOPRENALINE; ESMOLOL; ISOPRENALINE; LABETALOL; LATANOPROST; MEPINDOLOL; METIPRANOLOL; METOPROLOL; NORADRENALIN; PINDOLOL; PRACTOLOL; PRONETALOL; SALBUTAMOL; SOTALOL; TIMOLOL; UNINDEXED DRUG; XAMOTEROL;

BETA ADRENERGIC RECEPTOR BLOCKING; CORONARY ARTERY DISEASE; ESSENTIAL TREMOR; GLAUCOMA; HEART FAILURE; HUMAN; HYPERTHYROIDISM; MIGRAINE; MUSCLE HYPERTONIA; PHEOCHROMOCYTOMA; SHORT SURVEY; STEREOCHEMISTRY;

EID: 22244471981     PISSN: 00483664     EISSN: None     Source Type: Journal    
DOI: 10.1002/pauz.200400091     Document Type: Short Survey

References (15)

1. Gauthier, C., Leblais, V., Moniotte, S., Langin, D., and Balligand, J. L.: The negative inotropic action of catecholamines : role of beta3-adrenceptors. Can. J. Physiol. Pharmacol. (2000) 78, 681-690.
2. Kaumann, A. J., Molenaar, P.: Modulation of human cardiac function through 4 beta-adrenergic populations. Naunyn Schmiedeberg's Arch. Pharmacol. (1997) 355, 667-681.
3. Freddolino, P. L., Kalani, M. Y., Vaidehi, N., Floriano, W. B., Hall, S. E., Trabanino, R. J., Kam, V. W., Coddard, W. A. 3rd.: Predicted 3D structure for the human β2 adrenergic receptor and its binding site for agonists and antagonists. Proc. Natl. Acad. Sci. U.S.A. (2004) 101, 2736-41.
4. Blackburn, C. G., Byrne, L. J., Cullum, V. A., Farmer, J. B., Levy, G. P.: The pharmacology of 5-(2-t-butylamino-1-hydroxyethyl)salicyamide (AH 3474), a β-adrenoceptor blocking agent. J Pharm. Pharmacol. (1969) 21, 488-497.
5. Bilski, A. J., Halliday, S. E., Fitzgerald, J. D. and Wale, J. L.: The pharmacology of a beta 2-selective adrenoceptor antagonist (ICI 118551). J. Cardiovasc. Pharmacol. (1983) 5, 430.
6. Manara, L., Badone, D., Baroni, M., Boccardi, G., Cecchi, R., Croci, T., Giudice, A., Guzzi, U., Le Fur, G.: Aryloxypropanolaminotetralins are the first selective antagonists for atypical (β3) β-adrenoceptors. Pharmacol. Commun. (1995) 6, 251-258.
7. Sybertz, E. J., Sabin, C. S., Pula, K. K., van Der Vliet, G., Glennon, J., Gold, E. H., Baum, T.: Alpha- and beta adrenoceptor blocking properties of labetalol and its R,R-isomer, SCH 19927. J. Pharmacol. Exp. Ther. (1981) 218, 435-443.
8. Brittain, R. T., Drew, G. M., Levy, G. P.: The a-and β-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anaesthetized dogs and in isolated tissues. Br. J. Pharmacol. (1982) 77, 105-114.
9. Riva, E., Mennini, T., Latini, R.: The α-and β-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers. Br. J. Pharmacol. (1992) 104, 823-838.
10. Nichols, A., Sulpizio, A. C., Ashton, D. J., Hieble, J. P., Ruffolo, R. R. Jr.: The interaction of the enantiomers of carvedilol with α 1- and β1- adrenoceptors. Chirality (1989) 1, 265-270.
11. Yoshikawa, T., Port, J. D., Asano, K., Chidiak, P., Bouvier, M., Dutcher, D., Roden, R. L., Minobe, W., Trammel, K. D., Bristow, M. R.: Cardiac adrenergic receptor effects of carvedilol. Eur. Heart J. (1996) 17, B8-B16.
12. Neugebauer, G., Akpan, W., Kaufmann, B., Reiff, K.: Stereoselective disposition of carvedilol an amn after intravenous and oral administration of the racemic compound. Eur. J. Clin. Pharmacol. (1990) 38, 108-111.
13. Bristow, M. R., Roden, R. L., Lowes, B. D., Gilbert, E. M., Eichhorn, E. J.: The role of third generation b-blocking agents in chronic heart failure. Clin. Cardiol. (1998) 21, I-3-I-13.
14. Di Lenarda, A., Gilbert, E. M., Olsen, S. L., Mealey, P. C., Bristow, M. R.: Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. (1991) 17, 142A. Abstract.
15. Wuttke, H., Rau, T., Eschenhagen, T.: Genpolymorphismen in Arzneimittel-abbauenden Enzymen; Bedeutung für die Therapie mit β-Blockern. Dtsch. Med. Wochenschr. (2004) 129, 831-835.